Vicarious Surgical (RBOT) Long-Term Debt Repayments (2022 - 2023)

Vicarious Surgical (RBOT) reported Long-Term Debt Repayments of $4000.0 for Q2 2023, down 97.33% year-over-year from $150000.0 in Q2 2022, and down 66.67% on a QoQ basis from $12000.0 in Q1 2023.

Vicarious Surgical (RBOT) has 2 years of Long-Term Debt Repayments data on file, last reported at $4000.0 in Q2 2023.

  • Quarterly Long-Term Debt Repayments fell 97.33% year-over-year to $4000.0 in Q2 2023, while the trailing twelve-month figure through Dec 2023 was $16000.0 (down 98.81% YoY) and the FY2023 annual result came in at $16000.0, down 98.81% from the prior year.
  • Long-Term Debt Repayments eased to $4000.0 in Q2 2023 per RBOT's latest filing, from $12000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $900000.0 in Q4 2022 and bottomed at $4000.0 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Vicarious Surgical - - - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 4,000.00
Jun 30, 2023 4,000.00
Mar 31, 2023 12,000.00
Mar 31, 2023 12,000.00
Dec 31, 2022 900,000.00
Dec 31, 2022 900,000.00
Sep 30, 2022 150,000.00
Sep 30, 2022 150,000.00
Jun 30, 2022 150,000.00
Jun 30, 2022 150,000.00
Mar 31, 2022 150,000.00
Mar 31, 2022 150,000.00